Abstract
Systemic Sclerosis (SSc) is a complex multisystem disease characterized by vascular involvement and generalized disturbance of the microcirculation. Pulmonary vascular disease leads to systemic sclerosis-related pulmonary arterial hypertension (SScPAH). SScPAH is a devastating complication with a considerable impact on prognosis, being a common cause of disease-related death. The ability to detect this process at an early stage by simple means would be of great value, since effective treatment is now available. There is increasing evidence that several biomarkers increase in proportion to the extent of right ventricular dysfunction and correlate with hemodynamic, echocardiographic and functional measurements of pulmonary vascular disease. Biomarkers may be used to identify high-risk patients for more invasive procedures, provide prognostic information, and guide vasodilator therapy. In this article, we review potential biomarkers in SScPAH as tools for screening, diagnostic evaluation, risk stratification, prediction of disease severity and indicators of treatment efficacy.
Keywords: Systemic sclerosis, pulmonary hypertension, natriuretic peptides, asymmetric dimethylarginine, biomarkers, nitric oxide
Current Vascular Pharmacology
Title: Biomarkers in Systemic Sclerosis-Related Pulmonary Arterial Hypertension
Volume: 9 Issue: 2
Author(s): Theodoros Dimitroulas, Georgios Giannakoulas, Haralambos Karvounis, Loukas Settas and George D. Kitas
Affiliation:
Keywords: Systemic sclerosis, pulmonary hypertension, natriuretic peptides, asymmetric dimethylarginine, biomarkers, nitric oxide
Abstract: Systemic Sclerosis (SSc) is a complex multisystem disease characterized by vascular involvement and generalized disturbance of the microcirculation. Pulmonary vascular disease leads to systemic sclerosis-related pulmonary arterial hypertension (SScPAH). SScPAH is a devastating complication with a considerable impact on prognosis, being a common cause of disease-related death. The ability to detect this process at an early stage by simple means would be of great value, since effective treatment is now available. There is increasing evidence that several biomarkers increase in proportion to the extent of right ventricular dysfunction and correlate with hemodynamic, echocardiographic and functional measurements of pulmonary vascular disease. Biomarkers may be used to identify high-risk patients for more invasive procedures, provide prognostic information, and guide vasodilator therapy. In this article, we review potential biomarkers in SScPAH as tools for screening, diagnostic evaluation, risk stratification, prediction of disease severity and indicators of treatment efficacy.
Export Options
About this article
Cite this article as:
Dimitroulas Theodoros, Giannakoulas Georgios, Karvounis Haralambos, Settas Loukas and D. Kitas George, Biomarkers in Systemic Sclerosis-Related Pulmonary Arterial Hypertension, Current Vascular Pharmacology 2011; 9 (2) . https://dx.doi.org/10.2174/157016111794519381
DOI https://dx.doi.org/10.2174/157016111794519381 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Circulating Biomarkers for the Diagnosis and Prognosis of Heart Failure
Current Medicinal Chemistry Roles of Connexins in Atherosclerosis and Ischemia-Reperfusion Injury
Current Pharmaceutical Biotechnology Progress in Drug Treatment of Cerebral Edema
Mini-Reviews in Medicinal Chemistry Standardization of QRS Duration Measurement and LBBB Criteria in CRT Trials and Clinical Practice
Current Cardiology Reviews SIRT1 Promotes Neuronal Fortification in Neurodegenerative Diseases through Attenuation of Pathological Hallmarks and Enhancement of Cellular Lifespan
Current Neuropharmacology The Role for Oxidative Stress in Aberrant DNA Methylation in Alzheimer’s Disease
Current Alzheimer Research The Antagonists of Endothelin Receptors: Results and Perspectives
Current Pharmaceutical Analysis Non-Infectious Complications of Immunosuppressant Medications in Renal Transplant Patients
Current Clinical Pharmacology Anthracyclines Still Prove Effective in Anticancer Therapy
Mini-Reviews in Medicinal Chemistry Biologically Responsive Nanosystems Targeting Cardiovascular Diseases
Current Drug Delivery SALL4: Engine of Cell Stemness
Current Gene Therapy Membrane Lipids in the Function of Serotonin and Adrenergic Receptors
Current Medicinal Chemistry Leptin and the Cardiovascular System: A Review
Recent Patents on Cardiovascular Drug Discovery Cardiovascular Benefits of Extended-Time Nocturnal Hemodialysis
Current Vascular Pharmacology Aldehyde Dehydrogenase-2 Roles in Ischemic Cardiovascular Disease
Current Drug Targets Emerging Concepts on Inhibitors of Indoleamine 2,3-Dioxygenase in Rheumatic Diseases
Current Medicinal Chemistry Bedside Lung Ultrasound in the Care of the Critically Ill
Current Respiratory Medicine Reviews Adult Neural Stem Cell Therapy: Expansion In Vitro, Tracking In Vivo and Clinical Transplantation
Current Drug Targets Calcium Homeostasis and Kinetics in Heart Failure
Medicinal Chemistry Morpho-Functional Features of In-Vitro Cell Death Induced by Physical Agents
Current Pharmaceutical Design